Would we need to set up a Vet Portal for each doctor or just our hospital?

If you would like to set up accounts for the hospital, please send us a list of doctors' names and email addresses as well as any support staff who would need access to the Vet Portal. Each doctor can also register independently on the Vet Portal. Please note the report will be sent to the ordering veterinarian's email, not to all hospital accounts.

Other Questions

Back to Help Center

I have a patient with likely lymphoma/leukemia. For a blood sample, can I just submit an EDTA blood tube or do I still use the ImpriMed tubes (and if so, how many tubes and is an additional EDTA blood tube still needed with that)?

If the patient is suspected of leukemia, blood collected in the EDTA tube should be fine. If it is lymphoma, we might need FNA from the affected organ/lymph node. We can suggest FNA in ImpriMed media tube (1) and 2ml of blood sample in an EDTA tube.

What is the successful prediction rate for this test?

Positive predictive values for our AI-based drug response predictions are 80% or higher.

What does flow cytometry tell me about my patient’s specimen?

ImpriMed’s flow cytometry report provides comprehensive information about the specimen’s immunophenotype. B-cell and T-cell immunophenotypes are useful in determining lymphoma/leukemia subtype and prognosis. In addition, our panel of ten antigens can also be used in the diagnosis of T-zonal lymphoma, acute leukemia, and other diseases. Antigens levels reported are: CD21, CD79a, CD3, CD4, CD8, CD5, CD45, CD34, CD14, and MHC class II. For more information, see: https://pubmed.ncbi.nlm.nih.gov/26953614/

How much research do you have to support your results?

All of our products are thoroughly validated in-house using clinical outcomes data and we have published multiple peer-reviewed papers demonstrating the efficacy of our predictions (Veterinary Sciences and Veterinary and Comparative Oncology). We have run over 12,000 tests on hematopoietic cells, and over 4,000 canine patients that have benefited from our services. We believe we have more data on canine lymphoma than any other company in the world.

Is there any reason to believe that submitting another sample to you would provide any additional information or possible changes in treatment protocols now that we are almost 4 months into the treatment plan?

We would suggest you submit another FNA and blood samples to us WHEN the patient's lymphoma relapses. Relapse of lymphoma means that the cancer develops a resistance to certain chemo drugs in use. When this happens, the relapsed cancer cells are usually different from the ones investigated in the naive status, which led to different drug response predictions to the tested drugs. Therefore, it would be better to get new tumor samples and find out what are the new preferred drugs and which of the used drugs still remain effective or became resistant for the relapsed lymphoma. However, the best scenario is to maintain clinical remission for as long a period of time so that you don’t have to order another service from us! If a second service is needed, we offer a 50% discount for returning patients.